There has been remarkable growth in clinical trials investigating immunotherapies across the US, Europe, Japan, and China, with China experiencing the most rapid growth.
Immunotherapy trial starts currently account for almost half of all oncology trials with sites across the major regions. A decade ago, immunotherapy approaches were less frequent and favored evaluation of monotherapies, most often those targeting the PD1, PDL1, CTLA4 checkpoints. Over the last decade development focus has shifted to immunotherapy combinations especially combinations with other immunotherapy agents. This is primarily based on the principles of targeting multiple mechanisms at the immunologic checkpoint to achieve greater clinical efficacy. There has also been an increase in combination approaches with targeted therapies (such as TKIs) and non-targeted therapies (including chemotherapy and radiotherapy). These approaches areguided by principles of stimulating antigen release, impacting the micro-environment and improving immunologic traffiking.
To learn more about combinations approaches in immunotherapy contact us at oracle.com/life-sciences/
Copyright © 2023 Oracle and/or its affliates. All rights reserved.
Source: CancerMPact®: Cancer Landscape and Future Trends andInsights, accessed February 2, 2023 123456789_Infographic on immunotherapy combinations v1/April 2023